“Our SPAC team, led by partner Ari Edelman in New York, has seen a rapid uptick in the number of de-SPAC and SPAC IPO transactions it has advised on since last fall,” said James Tandler, chair of Reed Smith’s U.S. Corporate Group. “John has extensive experience working on various types of transactions, including de-SPAC transactions, and mergers and acquisitions in healthcare, technology, telecommunications, insurance, manufacturing, private equity and various other industry sectors.”

Most recently, the Reed Smith SPAC team represented SomaLogic, a global leader in proteomics technology, in its definitive business combination agreement with CM Life Sciences II, a SPAC sponsored by affiliates of Casdin Capital, LLC, and Corvex Management LP. In addition, the firm is representing a number of SPACs in their de-SPAC acquisitions, and represents numerous issuers and underwriters, including, Citi, Cantor Fitzgerald, B. Riley and Chardan, in SPAC IPOs.

“The explosion in the SPAC market has created huge growth opportunities for our clients, which, in turn, has significantly increased the demand from our clients for service,” said Jennifer Cheng, vice chair of the firm’s U.S. Corporate Group. “We are thrilled to add an attorney of John’s caliber and experience to the Reed Smith team.”